Introduction: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing–remitting (RR) MS. Methods: We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean ± SD) 46.1 ± 10.2 years, Expanded Disability Status Scale (EDSS) score 1.1 ± 1.2, timed 25-foot walk (T25FW) 4.6 ± 0.8 s] and eight patients on noDMT (age 42.5 ± 6.6 years, EDSS 1.7 ± 1.1, T25FW 4.4 ± 0.6 s). Baseline and 1-year 3D T1-weighted 3T MRI was processed with automated pipelines (SIENA, FSL-FIRST) to assess percentage whole brain volume cha...
Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable ben...
OBJECTIVE: The radiologically isolated syndrome (RIS) represents the earliest detectable pre-clinica...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Objective: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gas...
OBJECTIVE: In the pivotal DEFINE and CONFIRM trials for dimethyl fumarate (DMF), patterns of brain...
OBJECTIVE: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gas...
Background: Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-wo...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Background: A significant proportion of patients with multiple sclerosis (MS) show cognitive impairm...
BACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetat...
BACKGROUND: Two phase III trials have demonstrated the clinical and radiological efficacy of dela...
Background: Dimethyl-fumarate (DMF) was effective and safe in relapsing–remitting multiple sclerosis...
Introduction: Despite the increased availability of disease-modifying therapies (DMTs) for treating ...
Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable ben...
OBJECTIVE: The radiologically isolated syndrome (RIS) represents the earliest detectable pre-clinica...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...
Objective: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gas...
OBJECTIVE: In the pivotal DEFINE and CONFIRM trials for dimethyl fumarate (DMF), patterns of brain...
OBJECTIVE: To evaluate the effects of oral delayed-release dimethyl fumarate (DMF; also known as gas...
Background: Dimethyl fumarate (DMF) has demonstrated efficacy in phase III studies. However, real-wo...
<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....
Background: A significant proportion of patients with multiple sclerosis (MS) show cognitive impairm...
BACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetat...
BACKGROUND: Two phase III trials have demonstrated the clinical and radiological efficacy of dela...
Background: Dimethyl-fumarate (DMF) was effective and safe in relapsing–remitting multiple sclerosis...
Introduction: Despite the increased availability of disease-modifying therapies (DMTs) for treating ...
Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable ben...
OBJECTIVE: The radiologically isolated syndrome (RIS) represents the earliest detectable pre-clinica...
Background and purpose: Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately...